Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 13, 2010

Epitomics Spins Out Company to Focus on Therapeutic mAb Development

  • Epitomics has spun out Apexigen, which will focus on humanized mAbs for cancer and immune disorders. The new company was formed with exclusive rights to develop and commercialize therapeutic antibodies derived from Epitomics’ RabMAb® (rabbit mAb) technology and the Mutational Lineage Guided (MLG) humanization technology. Both platforms were developed by Epitomics for the treatment of human and animal diseases.

    A service agreement between Epitomics and Apexigen allows the latter immediate access to the antibody generation, screening infrastructure, and technical expertise of Epitomics. The company will assume development and commercialization of  programs initiated by Epitomics, including humanized antibodies against VEGF and TNF.

    "We believe that an independent company with experience, expertise, and focused pharmaceutical product development offers the best opportunity to see technology developed at Epitomics have a direct therapeutic impact on peoples' lives," says Guo-Liang Yu, president and CEO of Epitomics.

    "Epitomics will continue to focus on its core business and assist Apexigen as it develops therapeutics to treat serious diseases," Dr. Yu says. Epitomics is dedicated to developing mAb technology for research and diagnostic applications.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »